Difference between revisions of "Example orders for Cetuximab (Erbitux) in colon cancer"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth" to "{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | <span style="font-family:Arial; font-size:200%"> Hello!<br> We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br> Please help us by filling it out!<br> '''Link:''' http://j.mp/2BlBaoQ </span> |}<br>'''Use of this site is subject to you reading and agreeing with the terms set forth") |
Warner-admin (talk | contribs) m (Text replacement - " " to " ") |
||
| (12 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | + | <!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''--> | |
| − | |||
| − | < | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. | Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. | ||
| Line 24: | Line 17: | ||
'''28-day cycle''' | '''28-day cycle''' | ||
| − | ====Supportive | + | ====Supportive therapy==== |
| − | *Acetaminophen (Tylenol) 650 mg PO 30 minutes prior to cetuximab | + | *Acetaminophen (Tylenol) 650 mg PO once; 30 minutes prior to cetuximab |
*Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab | *Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab | ||
Hydration: | Hydration: | ||
| − | *500 ml NS at KVO rate as running IV for chemotherapy infusion. | + | *500 ml NS at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS. |
Monitoring: | Monitoring: | ||
| − | *Hold if ANC | + | *Hold if ANC less than 1000 or platelets less than 100 and notify physician. |
For cycle 2 and later: | For cycle 2 and later: | ||
*[[Cetuximab (Erbitux)]] 250 mg/m<sup>2</sup> IV over 60 minutes on days 1, 8, 15, 22 | *[[Cetuximab (Erbitux)]] 250 mg/m<sup>2</sup> IV over 60 minutes on days 1, 8, 15, 22 | ||
| Line 38: | Line 31: | ||
'''28-day cycles''' | '''28-day cycles''' | ||
| − | ====Supportive | + | ====Supportive therapy==== |
| − | *Acetaminophen (Tylenol) 650 mg PO 30 minutes prior to cetuximab | + | *Acetaminophen (Tylenol) 650 mg PO once; 30 minutes prior to cetuximab |
*Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab | *Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab | ||
Hydration: | Hydration: | ||
| − | *500 ml NS at KVO rate as running IV for chemotherapy infusion. | + | *500 ml NS at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS. |
Monitoring: | Monitoring: | ||
| − | *Hold if ANC | + | *Hold if ANC less than 1000 or platelets less than 100 and notify physician. |
'''Comments:''' | '''Comments:''' | ||
Latest revision as of 02:03, 1 June 2023
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
Cetuximab (Erbitux)
Original references may be found at Cetuximab (Erbitux)
Example regimen #1
For cycle 1:
- Cetuximab (Erbitux) 400 mg/m2 IV over 2 hours on day 1
- Use non-DEHP/paclitaxel tubing.
- Cetuximab (Erbitux) 250 mg/m2 IV over 60 minutes on days 8, 15, 22
- Use non-DEHP/paclitaxel tubing.
28-day cycle
Supportive therapy
- Acetaminophen (Tylenol) 650 mg PO once; 30 minutes prior to cetuximab
- Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab
Hydration:
- 500 ml NS at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS.
Monitoring:
- Hold if ANC less than 1000 or platelets less than 100 and notify physician.
For cycle 2 and later:
- Cetuximab (Erbitux) 250 mg/m2 IV over 60 minutes on days 1, 8, 15, 22
- Use non-DEHP/paclitaxel tubing.
28-day cycles
Supportive therapy
- Acetaminophen (Tylenol) 650 mg PO once; 30 minutes prior to cetuximab
- Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab
Hydration:
- 500 ml NS at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS.
Monitoring:
- Hold if ANC less than 1000 or platelets less than 100 and notify physician.
Comments:
- My institution uses 28-day cycles for Cetuximab (Erbitux) regimens.